alxoncology.com (ALXO): Rasio rega marang prakiraan pendapatan

ALXO (ALX Oncology Holdings Inc.) - tandha merek perusahaan

ALX Oncology Holdings (ALXO) previously funded clinical trials using existing cash reserves. The forward P/S ratio demonstrates the current market valuation, where the value reflects the metric's balance. Looking ahead, the safe drug evorpacept will provide a competitive edge in cancer therapy, while the unique method of blocking tumor signals will create the conditions for establishing significant pricing power.

ALXO ALX Oncology Holdings Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 18.11.2026

Rincian analitis perusahaan ALX Oncology (ALXO)

Ringkesan analisis perusahaan:alxoncology.com ALXO
Produk sing diprodhuksi alxoncology.com

For the non-cyclical biotech ALX Oncology Holdings (ALXO), whose value depends on scientific data rather than GDP, this indicator reflects the market value of every dollar of expected revenue. By analyzing the forward P/S ratio, an investor determines the degree of overpayment for future sales relative to historical averages, which allows for identifying an entry point with a margin of safety and minimizing the risks of capital freeze.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S MiNK Therapeutics Inc.|Rasio rega marang prakiraan pendapatan werewolftx.com (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP